AUGUSTUS试验事后分析:房颤合并近期ACS或PCI且有卒中史患者的阿哌沙班与阿司匹林治疗
该研究为AUGUSTUS试验的事后分析,纳入4581例房颤合并近期ACS和/或PCI患者,其中633例(13.8%)有卒中/TIA/血栓栓塞史。比较阿哌沙班或VKA及阿司匹林或安慰剂的效果,发现阿哌沙班较VKA降低出血和死亡/住院风险,且不受既往卒中史影响;阿司匹林增加出血,尤其在无卒中史患者中。
要点
- 阿哌沙班较VKA降低大出血或临床相关非大出血风险,无论有无卒中史。
- 阿司匹林增加出血风险,在无卒中/TIA/血栓栓塞史患者中更明显。
- 多数房颤合并ACS和/或PCI患者支持阿哌沙班加P2Y12抑制剂、不用阿司匹林。
核心结论
- 阿哌沙班相比VKA的安全性和有效性在有无卒中/TIA/血栓栓塞史患者中一致。
- 阿司匹林增加大出血或临床相关非大出血,尤其在无卒中/TIA/血栓栓塞史患者中。
- 结果支持多数房颤合并ACS和/或PCI患者使用阿哌沙班加P2Y12抑制剂、不用阿司匹林,无论既往卒中/TIA/血栓栓塞状态。
研究设计与样本
- AUGUSTUS试验的事后平行分析,采用2×2析因随机设计,使用Cox比例风险模型。
- 纳入房颤合并近期ACS或PCI且计划使用P2Y12抑制剂至少6个月的患者;排除33例缺失卒中/TIA/血栓栓塞数据的患者。
- 最终纳入4581例患者,其中633例(13.8%)有卒中/TIA/血栓栓塞史。
主要发现
- 有卒中/TIA/血栓栓塞史患者接受阿哌沙班 vs VKA的大出血或临床相关非大出血及死亡或住院HR为0.69(95%CI 0.46-1.03)。
- 无卒中/TIA/血栓栓塞史患者接受阿哌沙班 vs VKA的相应HR为0.68(95%CI 0.57-0.82)。
- 有卒中/TIA/血栓栓塞史患者阿司匹林 vs 安慰剂死亡或缺血事件HR为0.71(95%CI 0.42-1.20),无史者为0.93(95%CI 0.72-1.21),均无统计学显著性。
临床怎么用
- 对于房颤合并ACS和/或PCI的患者,多数应考虑阿哌沙班加P2Y12抑制剂、不用阿司匹林,无论既往有无卒中/TIA/血栓栓塞。
- 有卒中/TIA/血栓栓塞史的患者使用阿司匹林需谨慎,因出血风险仍存在但交互作用提示差异较小。
局限性
- 为事后分析,可能存在未测量混杂。
- 有卒中/TIA/血栓栓塞史亚组样本量有限(633例),部分比较未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Data are limited regarding the risk of cerebrovascular ischemic events and major bleeding in patients with atrial fibrillation (AF) and recent acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). OBJECTIVE: Determine the efficacy and safety of apixaban or vitamin K antagonists (VKA) and aspirin or placebo according to prior stroke, transient ischemic attack (TIA), or thromboembolism (TE). DESIGN, SETTING, AND PARTICIPANTS: In this prospective, multicenter, 2-by-2 factorial, randomized clinical trial, post hoc parallel analyses were performed to compare randomized treatment regimens according to presence or absence of prior stroke/TIA/TE using Cox proportional hazards models. Patients with AF, recent ACS or PCI, and planned use of P2Y12 inhibitors for 6 months or longer were included; 33 patients with missing data about prior stroke/TIA/TE were excluded. INTERVENTIONS: Apixaban (5 mg or 2.5 mg twice daily) or VKA and aspirin or placebo. MAIN OUTCOMES AND MEASURES: Major or clinically relevant nonmajor (CRNM) bleeding. RESULTS: Of 4581 patients included, 633 (13.8%) had prior stroke/TIA/TE. Patients with vs without prior stroke/TIA/TE were older; had higher CHA2DS2-VASC and HAS-BLED scores; and more frequently had prior bleeding, heart failure, diabetes, and prior oral anticoagulant use. Apixaban was associated with lower rates of major or CRNM bleeding and death or hospitalization than VKA in patients with (hazard ratio [HR], 0.69; 95% CI, 0.46-1.03) and without (HR, 0.68; 95% CI, 0.57-0.82) prior stroke/TIA/TE. Patients without prior stroke/TIA/TE receiving aspirin vs placebo had higher rates of bleeding; this difference appeared less substantial among patients with prior stroke/TIA/TE (P = .01 for interaction). Aspirin was associated with numerically lower rates of death or ischemic events than placebo in patients with (HR, 0.71; 95% CI, 0.42-1.20) and without (HR, 0.93; 95% CI, 0.72-1.21) prior stroke/TIA/TE (not statistically significant). CONCLUSIONS AND RELEVANCE: The safety and efficacy of apixaban compared with VKA was consistent with the AUGUSTUS findings, irrespective of prior stroke/TIA/TE. Aspirin increased major or CRNM bleeding, particularly in patients without prior stroke/TIA/TE. Although aspirin may have some benefit in patients with prior stroke, our findings support the use of apixaban and a P2Y12 inhibitor without aspirin for the majority of patients with AF and ACS and/or PCI, regardless of prior stroke/TIA/TE status. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02415400.
引用
- Bahit, Vora, Li, et al. Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial. JAMA Cardiol. 2022. PMID: 35612866. doi:10.1001/jamacardio.2022.1166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。